Full-Time
Sanofi
10,001+ employees
Develops pharmaceuticals and vaccines globally
No salary listed
Mid, Senior
Hyderabad, Telangana, India
Upload your resume to see how it matches 11 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- Project management experience required
- 3–5 years post qualification experience
- Advanced degree in life sciences/commerce/engineering/pharmacy/similar discipline
- Excellent knowledge of English language (spoken and written)
- Stakeholder management
- Writing/communication skills
- External engagement and ability to work independently and within a team environment
- Contracting, budgeting, vendor management, including but not limited publication ops support; and/or project management
- Work closely with Senior director (EBM strategic planning and operations), business partners, therapy areas lead, eBuy manager, external vendors, and finance colleagues to support coordination and management of various activities
- Work with TA Leads to conduct monthly/bimonthly/quarterly budget reviews and ensure full oversight; identify US budget needs; coordinate with cross-functional teams to operationalise strategic plan, brand plan and prioritization; identify areas of support needed; develop and maintain TA project tracker; to track and update on monthly worksheet issues flagged
- Work with business partners to perform monthly review of budget plans and actuals; complete North America (NA) intake form and update budget tracker with SOW details, shift funds on tracker to align with finance; provide updates on pending contracts, identify any challenges and follow-up on invoicing issues; follow-up on cross charges by end of November to make sure they hit the books; coordinate and assist to set-up Ad-board meetings
- Coordinate with ITA team for organising external meetings and activities such as GRFs, FMVs, tiering, honoraria tables and cost-sheet etc.
- Coordinate with finance colleagues to communicate any discrepancies between finance trackers and BPs budget tracker, cost centre mistakes and for any amendments as needed
- Work with vendors on contract support to onboard vendors; ensure final approved SOW is processed via NA Intake form, follow–up on contract and PO, forward PO to vendor; support with contract renewals or amendments; follow-up on PV training; monitor invoices to be processed; schedule meetings and prepare meeting minutes
- Responsible for project management support to the scientific writer and HEVA ensuring the end-to-end effective project delivery of the designated publication/medical education and HEVA deliverable across all phases
- Initiate submission (as required), amend submission based on comments (as required). Support the writer with the development of a scope of work; build plan and schedule for agreement with the internal stakeholders
- Arrange key internal and external stakeholder meetings. Track the delivery of activities (including managing issues and risks) and support follow up
- Support tracking GD requests and ensuring they are executed on time
- Support in and maintaining and tracking editorial and QC request for publications and other deliverables. Also make sure stipulated timelines are met
- Support required submission, compliance, and approval activities, and ensure compliance with publication processes and use of publication management tools
- Support the management of the assigned publication or medical education in line with the agreed budget. Support and manage as required external spend tracking (e.g., approvals, purchase orders, and goods received)
- Support HEVA team in fetching articles from Rightfind or relevant scientific databases
- Support HEVA team members in sourcing full texts of paid articles from other sources and managing their procurement processes as per the standard guidelines
- Support HEVA team in downloading and categorisation of booklets and information, respectively, from various congress websites as per the eligibility criteria
- Support adherence to associated compliance related activities and approvals (with internal stakeholder taking accountability for compliance)
- Update as required with approval/compliance tools (e.g., PromoMats, NAYA)
- Manage end to end process through Datavision, Matrix, RightFind, Ebuy, PrismAccess, etc.
- Collaborate effectively with stakeholders: Scientific communication global and/or local teams/HEVA teams; and medical content enhancement teams
- Maintain effective relationship with the end stakeholders (medical scientific community) within the allocated GBU and product – with an end objective to develop education and communication content as per requirement;
- Actively lead and develop SGH operations associates;
- Ensure new technologies are leveraged;
- Support vendor engagements, advisory boards scientific events activities & external expert contracts;
- Initiate the contracting process and related documents within defined timelines;
- Collaborate with global stakeholders for project planning and setting up the timelines and maintaining budget
- Coordinate all contracting and budgeting tasks diligently
- Work with HEVA TA Leads to conduct monthly/bimonthly/quarterly budget reviews and ensure full oversight
- Work with business partners to perform monthly review of budget plans and actuals
- Coordinate with ITA team for organising external meetings and activities
- Coordinate with finance colleagues to communicate all discrepancies
- Ensure publication/medical education materials (slide decks, abstracts, posters, manuscripts, newsletters, pub alert, etc.) are delivered, stored as per agreed timelines and quality;
- Develop tools, technology, and process to constantly improve quality and productivity;
- Support SGH HEVA team in timely review and audit of all DataVision entries;
- Support SGH HEVA team in all operations related projects;
- Perform quality check for HEVA documents;
- Maintain HEVA Smartsheet/projects trackers as needed and make sure all entries are up to date for all projects and;
- Support global HEVA team to maintain trackers and facilitate retrieval of required information for business reviews as needed
- Work with vendors on contract support to onboard vendors
- Medical communication/pharma experience desirable
Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical needs. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline and a global presence. The company's goal is to enhance health outcomes and improve the quality of life for people worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Simplify's Take
What believers are saying
- Tolebrutinib's potential approval could establish Sanofi as a leader in MS treatment.
- Sanofi's acquisition of Dren Bio enhances its biopharmaceutical capabilities and market reach.
- Expansion into personalized medicine offers new opportunities for targeted therapies.
What critics are saying
- Increased competition in MS treatment could impact tolebrutinib's market share.
- Regulatory delays for tolebrutinib in the US and EU may affect revenue projections.
- The €5 billion share buyback program could limit investment in strategic initiatives.
What makes Sanofi unique
- Sanofi's tolebrutinib targets non-relapsing secondary progressive multiple sclerosis, a unique market niche.
- The company leverages mRNA technology for vaccines beyond COVID-19, expanding its portfolio.
- Sanofi's focus on patient-centric solutions aligns with the growing trend of value-based healthcare.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved. These findings further support the differentiated mechanism of oral, brain-penetrant tolebrutinib, targeting disability progression independent of relapse activity. These results were first presented at the ECTRIMS conference on September 20, 2024 in Copenhagen, Denmark and further analyses were also presented today during the Clinical Trials Plenary Session at the 2025 Annual Meeting for the American Academy of Neurology (AAN) in San Diego, California.Robert Fox, MDVice Chair of Research at Cleveland Clinic’s Neurological Institute, Cleveland, Ohio, US, and chair of the HERCULES global steering committee“Tolebrutinib represents a new class of therapy for the treatment of multiple sclerosis. In this large phase 3 study, tolebrutinib was found to slow the progression of disability in a subset of multiple sclerosis for which we have no approved therapies – non-relapsing secondary progressive disease. The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.”Dr Fox is a paid advisor to Sanofi for the HERCULES study.Erik Wallström, MD, PhDGlobal Head of Neurology Development“By targeting disability progression mechanisms behind the blood-brain barrier, tolebrutinib has the potential to be a practice-changing therapeutic option for people living with multiple sclerosis
If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activityTolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MSTolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MSParis, March 25, 2025. The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. The target action date for the FDA decision is September 28, 2025. A regulatory submission is also under review in the EU.The regulatory submissions in the US and the EU are supported by the results from the phase 3 studies HERCULES in nrSPMS and GEMINI 1 and 2 in relapsing MS (RMS). The findings from these studies, as well as additional clinical and preclinical studies, support the differentiated mechanism of tolebrutinib to target disability progression independent of relapse activity, and the scientific hypothesis that smoldering neuroinflammation represents a key inflammatory process in MS and is a critical driver of disability accumulation.Erik Wallström, MD, PhDGlobal Head of Neurology Development“The totality of data across our clinical program validates our scientific understanding of smoldering neuroinflammation as a distinct inflammatory process in MS. People living with non-relapsing secondary progressive multiple sclerosis or who experience disability independent of relapse activity suffer from disability that worsens over time due to persistent inflammation in the brain, known as smoldering neuroinflammation, which is the primary driver of disability
Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website:First quarter 2025 (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's first quarter 2025 results will be published on April 24, 2025.About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.comEvan Berland | + 1 215 432 0234 | evan.berland@sanofi.comNicolas Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.comLéo Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.comVictor Rouault | + 33 6 70 93 71 40 | victor.rouault@sanofi.comTimothy Gilbert | + 1 516 521 2929 | timothy.gilbert@sanofi.comInvestor RelationsThomas Kudsk Larsen | + 44 75 45 51 36 93| thomas.larsen@sanofi.comAlizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.comFelix Lauscher | + 1 908 612 7239 | felix.lauscher@sanofi.comKeita Browne | +1 781 249 1766 | keita.browne@sanofi.comNathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.comTarik Elgoutni | + 1 617 710 3587 | tarik.elgoutni@sanofi.comThibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.comYun Li | + 33 6 84 00 90 72 | yun.li3@sanofi.comForward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended
Pharma-major Sanofi has acquired Serbian-founded biopharmaceutical company Dren Bio for up to $1.9bn, the companies announced in a press release on ...
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic, debilitating, and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin, and painful lesions.Victoria Werth, MDChief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Professor of Dermatology and Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, and principal investigator of the study“People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce disease severity and itch compared to placebo in a clinical study.”The ADEPT study met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial loading dose or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained